Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Herpesviridae Infections 1HIV Infections 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Acquired Immunodeficiency Syndrome 1AIDS-Related Opportunistic Infections 1

Interventions

Leucovorin 6Cyclophosphamide 6Vincristine 5Methotrexate 5Cytarabine 5Mercaptopurine 4Dexamethasone 4Daunorubicin 4Thioguanine 3Specimen Handling 3Prednisolone 3Methylprednisolone 3Hydrocortisone 3Doxorubicin 3Asparaginase 3merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2blinatumomab 2azathiopurine 2auricularum 2Sunitinib 2Peripheral Blood Stem Cell Transplantation 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Carboplatin 2Calcium Dobesilate 2venetoclax 1uproleselan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Biphenotypic, Acute × Acyclovir × Clear all
NCT00061945 2022-05-03

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
302 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡